EIC Fund backs Xenothera with roughly €12 million to develop polyclonal antibody COVID-19 therapy
- ›The European Innovation Council Fund committed equity to support Nantes-based Xenothera’s COVID-19 antibody candidate XAV-19.
- ›The EIC financing combines an equity decision of about €10 million and an EIC Accelerator grant of €2.16 million, a total commonly reported as €12 million though the components add to €12.16 million.
- ›Xenothera’s XAV-19 is a polyclonal antibody therapy produced with a proprietary platform; regulators have given Rapid Scientific Advice and CHMP feedback supporting the development approach.
- ›The investment is presented as part of a broader EIC Fund push to crowd in private capital and scale deep tech health companies across Europe.
EIC Fund backs Xenothera to advance polyclonal antibody candidate XAV-19
On 29 June 2021 the European Innovation Council (EIC) Fund announced financing to support Xenothera, a Nantes based biotech, in the clinical development of an anti-COVID-19 therapeutic called XAV-19. The public announcement frames the transaction as a roughly €12 million commitment combining equity and grant support.
What the investment comprises
The public sources state two component amounts. The EIC Fund approved an equity investment of approximately €10 million and the company received a separate €2.16 million grant through the EIC Accelerator programme. Those two figures sum to €12.16 million, while the headline rollout repeatedly refers to the investment as €12 million. The difference is small but noteworthy for transparency when reconciling public announcements.
| Instrument | Amount (reported) | Notes |
| EIC Fund equity investment | €10,000,000 | Equity component managed under the EIC Fund |
| EIC Accelerator grant | €2,160,000 | Non-dilutive grant for clinical and development activities |
| Total reported in press statements | €12,000,000 | Headline figure; detailed components sum to €12.16 million |
The therapy: XAV-19 and Xenothera’s approach
Regulatory status and agency interactions
The European Medicines Agency provided Rapid Scientific Advice to Xenothera regarding XAV-19 market authorisation. The EMA Committee for Medicinal Products for Human Use offered endorsement of the approach described by the company, specifically noting the quality of XAV-19, the validity of preclinical and toxicology data, and the overall clinical development plan. Rapid Scientific Advice is an expedited advisory interaction and is not an approval. It is helpful to developers but it does not replace formal marketing authorisation processes. The company will still need to demonstrate safety and efficacy through clinical trials and complete the usual regulatory steps required for authorisation.
Why EIC Fund financing matters for biotech scale up
The EIC Fund combines grant and equity instruments to move high risk, deep tech projects toward commercialisation. In this case the EIC’s blended support is intended to help cover the resource heavy clinical development and manufacturing scale tasks that small biotech firms confront before they can reach larger funding rounds or partnering agreements with global pharmaceutical companies.
Context for applicants and European innovation policy
Public investment vehicles like the EIC Fund aim to close what is often called the European ‘scale‑up gap’ for deep tech firms. By providing patient capital and linking grant support to equity, the intent is to help companies cross development inflection points. This is particularly visible in health technologies where clinical development is capital intensive and carries substantial technical and regulatory risk.
Caveats, open questions and risks
Next steps for Xenothera and indicators to watch
Key milestones to follow will include detailed readouts from ongoing or future clinical trials, regulatory interactions beyond Rapid Scientific Advice, manufacturing scale up plans, partnerships or co‑investment rounds that the EIC Fund intends to catalyse, and any updates on efficacy against new viral variants. For the EIC Fund the important indicators will be whether the financing unlocks private co-investment and whether development progresses to market enabling outcomes.
What this says about Europe’s innovation approach
The transaction illustrates a distinctively European model of combining grants and public equity to support deep tech health ventures. The approach aims to maintain technology and IP value within Europe and to reduce dependency on non EU capital. That objective is politically resonant and strategically coherent. It is still early to judge whether the public investment model will consistently produce market success in high risk sectors such as therapeutics, which remain dependent on clinical results and commercial partnerships.
For readers tracking public funding of biotech, the Xenothera case is a useful example of how blended finance is being deployed. It is equally a reminder that favourable regulatory advice and public equity are helpful but not decisive. Clinical data, manufacturing execution and market fit will determine whether XAV-19 delivers the impact its backers hope for.
Sources and further reading
This article is based on the EIC press announcement dated 29 June 2021 and on publicly available material from the European Innovation Council and Xenothera. Additional context on the EIC Fund structure and objectives is drawn from EIC programme documentation published by the European Commission and EISMEA. Readers should consult the EMA and company disclosures for the most up to date clinical and regulatory information.